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Abstract
Background: Standard therapy for Glioblastoma multiforme (GBM) involves maximal safe tumor resection followed
with radiotherapy and concurrent adjuvant temozolomide. About 20 to 30% patients undergoing their first
post-radiation MRI show increased contrast enhancement which eventually recovers without any new
treatment. This phenomenon is referred to as pseudoprogression. Differentiating tumor progression from
pseudoprogression is critical for determining tumor treatment, yet this capacity remains a challenge for
conventional magnetic resonance imaging (MRI). Thus, a prospective diagnostic trial has been established
that utilizes multimodal MRI techniques to detect tumor progression at its early stage. The purpose of this
trial is to explore the potential role of intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI)
and three-dimensional arterial spin labeling imaging (3D-ASL) in differentiating true progression from
pseudoprogression of GBM. In addition, the diagnostic performance of quantitative parameters obtained
from IVIM-DWI and 3D-ASL, including apparent diffusion coefficient (ADC), slow diffusion coefficient (D),
fast diffusion coefficient (D*), perfusion fraction (f), and cerebral blood flow (CBF), will be evaluated.
Methods: Patients that recently received a histopathological diagnosis of GBM at our hospital are eligible for
enrollment. The patients selected will receive standard concurrent chemoradiotherapy and adjuvant
temozolomide after surgery, and then will undergo conventional MRI, IVIM-DWI, 3D-ASL, and contrast-
enhanced MRI. The quantitative parameters, ADC, D, D*, f, and CBF, will be estimated for newly developed
enhanced lesions. Further comparisons will be made with unpaired t-tests to evaluate parameter performance
in differentiating true progression from pseudoprogression, while receiver-operating characteristic (ROC)
analyses will determine the optimal thresholds, as well as sensitivity and specificity. Finally, relationships
between these parameters will be assessed with Pearson’s correlation and partial correlation analyses.
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Discussion: The results of this study may demonstrate the potential value of using multimodal MRI
techniques to differentiate true progression from pseudoprogression in its early stages to help decision
making in early intervention and improve the prognosis of GBM.
Trial registration: This study has been registered at ClinicalTrials.gov (NCT02622620) on November 18, 2015
and published on March 28, 2016.
Keywords: Glioblastoma multiforme, True progression, Pseudoprogression, Intravoxel incoherent motion
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Highlights
 Intravoxel incoherent motion (IVIM) magnetic
resonance imaging (MRI) allows the simultaneous
acquisition of diffusion and perfusion parameters
which reflect tumor cellularity and vascularity,
respectively.
 Arterial spin labeling (ASL) and IVIM are two
commonly used perfusion MRI techniques without
introducing contrast agents and are considered as
safe and reliable methods.
Background
Glioblastoma multiforme (GBM) is the most common
malignant primary brain tumor in adults. A combination
of radiation therapy with concurrent or adjuvant temo-
zolomide (TMZ) following maximum safe tumor resec-
tion can significantly improve patients’ survival, and is
currently the standard treatment for GBM. Even with
this standard treatment, the survival of GBM patients
remains extremely poor and the overall median survival
time is 14–18 months after treatment [1, 2].
GBM treatment efficacy is generally evaluated with
contrast-enhanced MRI in conjunction with clinical as-
sessment. Only recently have radiologists and clinicians
observed some transient treatment-induced changes
after radiotherapy which demonstrate tumor progression
features in contrast-enhanced MRI such as progressive
enlargement and new enhancement. However, these
features mainly derive from postsurgical changes includ-
ing radiation effects, treatment-induced inflammation,
and ischemia [3, 4]. This phenomenon is referred to as
pseudoprogression. Chemotherapy with TMZ signifi-
cantly increased the rate of pseudoprogression [5, 6]. It
is reported that half of the patients with high-grade
gliomas after chemoradiotherapy showed an enlarged
enhancement area on contrast-enhanced T1-weighted
magnetic resonance (MR) images, of which 20 to 30%
were pseudoprogression [7–9].
While both tumor progression and pseudoprogression
exhibit progressive enlargement and new enhancement
within a radiation field [3], the treatment and prognosis
for them are totally different. Tumor progression reflects
treatment failure and the treatment plan should be
adjusted accordingly [10], while pseudoprogression is
associated with a favorable prognosis and can improve
spontaneously with adjuvant TMZ. If the latter is mis-
diagnosed as true progression, the treatment efficacy can
be underestimated, thus leading to the inappropriate
adjust of therapy. However, true progression can not be
easily differentiated from pseudoprogression with current
conventional MRI sequences. Therefore, new imaging
tools that can assist clinicians in effectively identifying true
progression versus pseudoprogression within 6 months
after concurrent chemoradiotherapy are needed, which
will facilitate the selection of appropriate treatment or the
early termination of an invalid treatment plan.
There have been several studies in which researchers
differentiated true progression from treatment effects by
using advanced MR imaging techniques, such as diffusion
weighted magnetic resonance imaging (DWI) and dy-
namic susceptibility-weighted contrast-enhanced (DSC)
MRI. True progression exhibits significantly lower appar-
ent diffusion coefficient (ADC) values compared with
pseudoprogression [11, 12], reflecting the high cellularity
of progressed tumor. Considering that ADC values can be
compromised by perfusion, Le Bihan et al. introduced an
intravoxel incoherent motion (IVIM) technique [13, 14].
Slow diffusion coefficient (D) is the diffusion parameter
which reflects the diffusion coefficient for water while fast
diffusion coefficient (D*) represents perfusion-related
diffusion. Fraction of fast ADC (f) is the perfusion fraction
linked to microcirculation which has been successfully
applied to glioma grading and to differentiate recurrent
tumors from treatment-related changes [15, 16]. DSC is a
T2*-weighted technique to measure relative cerebral
blood volume (rCBV) and lower mean rCBV values in
pseudoprogression was previously used to differentiate
from true progression [17]. However, radiotherapy and
chemotherapy for GBM destroy blood–brain barrier,
allowing gadolinium-based contrast agents to leak into the
interstitial fluid, which may lead to the underestimation of
rCBV with DSC [18]. Three-dimensional arterial spin
labeling (3D-ASL) is another non-invasive and contrast
Liu et al. BMC Medical Imaging  (2017) 17:10 Page 2 of 7
agent-free perfusion imaging method to measure cere-
bral blood flow (CBF) [19]. The diagnostic perform-
ance of 3D-ASL has been found to be equivalent to
DSC MRI in assessing brain tumor perfusion, particu-
larly for those patients not suitable for DSC because
of renal failure [20].
Despite the application of IVIM and 3D-ASL in glioma
study, there still lacks study in which IVIM is combined
with 3D-ASL in the same GBM patient cohort to evalu-
ate their efficacy of differentiate true tumor progression
from pseudoprogression as a consequnence of radioche-
motherapy for GBM.
Therefore, the current prospective diagnostic trial was
designed to evaluate the ability of IVIM-DWI and 3D-
ASL to distinguish true tumor progression from pseudo-
progression in GBM. The diagnostic performance of the
quantitative parameters obtained from IVIM-DWI and
3D-ASL will also be compared.
Methods/Design
This prospective single institution observational study
will include two case groups and has been approved by
the Ethics Committee of Tangdu Hospital (TDLL-




Patients that recently received a histopathological diag-
nosis of GBM from Tangdu Hospital are considered for
enrollment in the present study. The criteria for selec-
tion are: (1) a recent histopathologic diagnosis of GBM
according to criteria of the World Health Organization;
(2) total or partial resection of the enhanced tumor com-
ponent; (3) baseline contrast-enhanced MRI performed
within 24 ~ 48 h after surgery; (4) standard radiation
therapy with concurrent TMZ and six cycles of adjuvant
Fig. 1 Flowchart of the current prospective diagnostic trial
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TMZ after surgery; (5) follow-up IVIM-DWI and 3D-
ASL performed on the same 3 T MRI scanner within
6 months after the completion of radiation therapy with
concurrent TMZ, when pseudoprogression is prevalent
[21], however as a long project, we will follow up glioma
patients as long as possible;(6) Without receiving cor-
ticosteroid management at 3 days before imaging;(7) the
presence of newly developed enhanced lesions or en-
larged enhanced lesions within the radiation field; (8)
surgical resection of enhanced tissue or adequate clini-
coradiologic follow-up to definitively diagnose true pro-
gression or pseudoprogression according to Response
Assessment in Neuro-Oncology (RANO) criteria [22].
Exclusion criteria
Subjects will be excluded based on any of the following
conditions: (1) without contrast-enhanced MRI per-
formed within 24 ~ 48 h after surgery; (2) absence of
newly developed enhanced lesions or enlarged enhanced
lesions after the end of radiation therapy with concur-
rent TMZ; (3) non-standard treatment after surgery; or
(4) patient does not complete clinicoradiologic follow-up
or surgical resection of enhanced tissue to definitively
diagnose true progression or pseudoprogression.
IVIM model
DWI dada will be analyzed using the same protocol as
described in our previous publication [15]. DWI will be
analyzed with an IVIM model (Eq. 1), where S0 and S(b)
are the signal intensities of attenuation at a b-value of 0 s/
mm2 and at a b-value > 0 s/mm2, respectively. D is the
diffusion parameter which reflects the diffusion coefficient
for water, D* represents perfusion-related diffusion and f
is the perfusion fraction linked to microcirculation.
Considering that D* is significantly larger than D [14, 23].
The contribution of D* to signal decay can be neglected
with a b-value > 200 s/mm2. Thus, Eq. (1) can then be sim-
plified, and the estimation of D can be obtained by using
only b values larger than 200 s/mm2, with a simple linear
fit Eq. (2), then D* and f will be generated with low b-values
by using a nonlinear regression algorithm based on Eq. (1).
S bð Þ =S0 ¼ f exp −b Dð Þ þ 1−fð Þ exp −b Dð Þ ð1Þ
S bð Þ =S0 ¼ exp −bDð Þ ð2Þ
The ADC value will be derived from a monoexponential
equation with all b-values by Eq. (3).
S bð Þ =S0 ¼ exp − ADC  bð Þ ð3Þ
Image acquisition
Upon completion of radiation therapy with concurrent
TMZ, follow-up MRI scans will be performed with a
3.0 T MRI system (MR750; GE Healthcare, Milwaukee,
WI, USA) with an 8-channel head coil. Conventional
MRI, DWI with 13 b-values (0 ~ 1500 s/mm2), 3D-ASL,
and contrast-enhanced MRI will be arranged in regular
sequence for each patient’s first follow-up visit. Conven-
tional MRI sequences will include spin-echo T1-weighted
imaging, fast spin-echo T2-weighted imaging, and fluid-
attenuated inversion recovery imaging (FLAIR). The IVIM
DWI will be performed prior to gadolinium injection with
a single-shot diffusion-weighted spin-echo echo-planar
sequence using 13 different b-values: 0, 10, 20, 30, 50, 80,
100, 200, 300, 500, 800, 1000, and 1500s/mm2. These
b-values were selected to cover both initial pseudo
diffusion decay (b < 200 s/mm2) and molecular diffu-
sion decay (b ≥ 200 s/mm2) [24]. In total, 20 axial
slices covering the entire brain will be obtained. The
following MR imaging parameters will be used: field
of view (FOV) = 256 × 256 mm2, slice thickness = 5 mm,
slice gap = 1.5 mm, repetition time (TR) = 3000 ms, echo
time (TE) =minimum, matrix =128 × 128. The total
acquisition time will be 5 min and 45 s.
A 3D spiral fast spin echo (FSE) sequence will be used
to obtain 3D-ASL perfusion images. The MRI parameters
will be: 512 sampling points on eight spiral arms, spatial
resolution = 3.64 mm, TR = 4590 ms, TE = 10.5 ms, slice
thickness = 4.0 mm, number of slices = 40, FOV = 240 ×
240 mm2, number of excitations (NEX) = 3.0. The total
acquisition time will be 4 min.
Finally, a contrast-enhanced T1-weighted spin echo
sequence will be performed in the transverse, sagittal,
and coronal planes following a bolus injection of 0.1 mmol/
kg of gadodiamide (Omniscan; GE Healthcare, Co.
Cork, Ireland).
Image analysis
All imaging data will be transferred to a GE ADW4.6
workstation. All of the IVIM-DWI and 3D-ASL parame-
ters will be measured by two experienced neuroradiologist
in consensus (SYZ, TQ, with 9 and 8 years of clinical ex-
perience in neuroradiology), who are blinded to the clin-
ical outcome. The conventional plain, contrast-enhanced
MRI scans will be carefully reviewed to detect if there are
newly developed enhanced lesions within the radiation
field. The section containing the maximum diameter of
the enhanced lesion will be selected for subsequent re-
gions of interest (ROI) analysis. ROI will be manually ex-
tracted to cover as much of the solid parts of the
enhanced lesions as possible on a single section, while
avoiding large vessels and hemorrhagic, ischemic, cystic,
and necrotic areas according to the anatomical contrast
images. The ROI will be transferred to the IVIM
parametric maps. Diffusion and perfusion parameter
maps of the IVIM will be generated automatically and
the parameters will be obtained from the ROI, includ-
ing mean ADC, D, D*, and f.
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ROI analysis for 3D-ASL will be performed in a
manner similar to that of IVIM-DWI. A single con-
trast section containing the maximum diameter of the
enhanced lesion will be selected, and an ROI will be
drawn around the entire enhanced lesion, while avoid-
ing large vessels and hemorrhagic, ischemic, cystic,
and necrotic areas according to the anatomical con-
trast images. The ROI will be transferred to the 3D-
ASL parametric maps. the mean CBF parameters will
be generated automatically.
Follow-up and lesion diagnosis
Serial follow-up MRI assessments will be performed
approximately 2 months after the completion of
standard radiation therapy with concurrent TMZ.
Disease progression will be definited according to
RANO criteria or histopathology of surgical resection.
If the size of the enhanced lesions remain unchanged
or show a decrease for at least 6 months, pseudo-
progression will be defined. On the contrary, if the
enhanced lesions exhibit a gradual increase in size for
at least 6 months, true progression will be defined.
Radiological evaluation will be made by two authors
in consensus (SYZ, TQ with 9 and 8 years of clinical
experience in neuroradiology).. Pseudoprogression
will be defined as some treatment effects with the
complete absence of tumor. Recurrent tumor will be
defined as any amount of tumor. Pathologic evalu-
ation will be made by an experienced neuropatholo-
gist (WZ, with 26 years of clinical experience in
neuropathology).
Sample size calculation and statistics
A sample size calculation was performed with refer-
ence to a previous study that had a sensitivity of 71.0%
and a specificity of 75.0% [16]. With a permissible
error of 0.1 and an alpha significance level of 0.05, a
sample size of 50 patients per group was enough to
get satisfying statistic power.
Numerical variables will be expressed as the mean
± standard deviation (SD). Student’s t-test will be
used to assess significant differences in the above
mentioned parameters between the true tumor pro-
gression and the pseudoprogression cases. Receiver
operating characteristic (ROC) analyses will deter-
mine corresponding specificity, sensitivity and cutoff
points for differentiating true tumor progression from
pseudoprogression based on ADC, D, D*, f, and CBF
values. Associations between f, D, and corresponding
CBF and ADC will be assessed with Pearson’s correl-
ation and partial correlation analyses, respectively.
SPSS 17.0 software (SPSS Inc, Chicago, IL, USA) will
be used for all statistical analyses and p < 0.05 indi-
cate statistical significance.
Primary outcome measure
(1) Differences in diffusion-related parameters between
true tumor progression and pseudoprogression
according to the different fitting model
D and ADC will be derived from biexponential and
monoexponential models, respectively. We
hypothesized that true tumor progression and
pseudoprogression can be distinguished based on
these two values and true tumor progression can
exhibit significantly lower mean D and ADC values
compared with pseudoprogression. In addition, we
hypothesized that D, which separates perfusion
effects, will be a more promising parameter in
distinguishing true tumor progression from
pseudoprogression compared with ADC which can
be compromised by perfusion.
(2) Differences in perfusion-related parameters between
true progression and pseudoprogression
Data regarding D*, f, and CBF will be summarized.
We hypothesized that D*, f, and CBF will
significantly differ between true tumor progression
and pseudoprogression and Mean D*, f, and CBF
values will be signifcantly lower for
pseudoprogression than for true progression.
(3) Diagnostic Performance of the IVIM and 3D-ASL
Parameters
Receiver operating characteristic (ROC) analyses
will determine corresponding cutoff points for
differentiating true tumor progression from
pseudoprogression based on ADC, D, D*, f, and
CBF values. In addition, sensitivity, specificity, and
area under curve (AUC) for identifying true
progression will be calculated in each case when
pseudoprogression is differentiated. We will make a
comparison among all the IVIM and 3D-ASL pa-
rameters to identify which has the best sensitivity/
specificity with regards to early diagnosis.
(4) Establishment of Clinical prediction model
Single factor analysis will show which covariates
affect the judgment of newly developed enhanced or
enlarged enhanced lesions, such as age, gender,
radiation dose, karnofsky performance score, lesion
region and imaging characteristics. A logistic
regression equation will be performed to identify
those covariates, IVIM and 3D-ASL parameters that
contribute to the diagnostic differentiation between
true progression and pseudoprogression.
Secondary outcome measures
(1) Correlations among imaging parameters
Correlation coefficients between f and
corresponding CBF values, and between D derived
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from the biexponential model and corresponding
ADC values derived from the monoexponential
model, will be calculated. It is hypothesized that
both sets of correlations will be significant.
Discussion
In patients with GBM after concurrent chemoradiother-
apy, it is important to differentiate pseudoprogression
from true progression to choose appropriate treatment
and predict prognosis. In both situations, conventional
MRI usually shows enhanced lesion with or without
mass effect, so it cannot be conclusive. Few studies have
examined the combination of IVIM and 3D-ASL im-
aging for distinguishing true progression from pseudo-
progression of GBM, The current study attempts to
validate perfusion and diffusion parameters derived from
IVIM and 3D-ASL to determine whether an enlarged
contrast-enhanced lesion was caused by true progression
or by pseudoprogression. Advantages and disadvantages
of this study are discussed below.
Compared to recently published studies in gliomas
[15, 25], more and higher b values are used in our study,
as more b values in segment of low b values can improve
the accuracy of the pseudodiffusion, while higher b
values can better eliminate the perfusion-related diffu-
sion; thus it can in turn generate a more realistic mo-
lecular diffusion coefficient value. Perfusion imaging of
brain tumors, which mainly includes DSC-MR perfusion
techniques, has been used for the diagnosis of glioma
recurrence and radiation necrosis [26–28]. However, the
use of intravenous contrast media is a major limitation
in the routine clinical application of this method, since
contrast media extravasation can result in a decreased
rCBV for high-grade tumors. The 3D-ASL is one sub-
method of ASL. It had been widely used in gliomas
grading and had reliable results with DSC. In this tech-
nique, the contrast agent used is labeled arterial blood
water proximal to the brain. Without intravenous
contrast media, 3D-ASL imaging could be particularly
relevant for the long-term follow-up of gliomas follow-
ing radiation, including those with renal insufficiency or
severe allergies. Several reports [26–28] have suggested
that combining information derived from different tech-
niques increases diagnostic performance not only for the
identifcation of brain tumors but also for assessing the
response to treatment. Because each parameter can
show different aspects of tumor biology, the combin-
ation of parameters may have added value compared
with single-parameter measurements.
We are expecting that combination of IVIM-DWI and
3D-ASL imaging has an acceptable accuracy in differenti-
ating true progression from pseudoprogression However,
there are several limitations of our study. First, patient
recruiting is difficult. Second, manual ROI measurements
that encompassed the entire lesion and targeted the areas
of maximal abnormality is used to measure the parame-
ters rather than a pixel-to-pixel method. This method may
not reflect the intraregional tumor heterogeneity. How-
ever, these techniques are rapid, reproducible, simple, and
are commonly used in clinical practice. Third, pathologic
sampling regions lacks strict pathologic correlation of the
image-based segmentation with surgical specimens, as
shown by Hu et al. [10]. However, in clinical practice, such
quantitative correlation is very difficult to achieve.
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